Ashley Abel, driven by the limitations of animal models in understanding human-specific diseases, co-founded Metri Bio in 2024. The biotechnology company focuses on developing new therapies for endometrial conditions, starting with endometriosis.
Metri Bio utilizes unique, patient-derived human tissue models to better understand the complex biology of endometriosis. Current treatments, primarily hormonal suppression and surgery, often fall short, with high recurrence rates and significant patient impact beyond fertility, including debilitating pain and increased cardiovascular risk.
The company raised $5 million pre-seed to industrialize its platform and identify novel disease targets. This approach aims to overcome the lack of widely agreed-upon disease markers in endometriosis research, enabling better patient stratification and the development of targeted, disease-modifying therapeutics.
Metri Bio's work, including its acceptance into the Milken Institute Women's Health Network chaired by former first lady Dr. Jill Biden, underscores its commitment to rigorous scientific advancement for patients. Abel, a Forbes 30 under 30 honoree, aims to deliver true disease-modifying effects for endometriosis and potentially other uterine conditions like fibroids.